23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › VERONA PHARMA PLC › 2023-2024

VERONA PHARMA PLC 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and VERONA PHARMA PLC’s Form 8-K, filed April 30, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 15Reported items
  • 126Asset managers, any item
  • 974Fund votes
  • April 26, 2024Meeting date

Results at a glance

Meeting of April 26, 2024: 14 items on VERONA PHARMA PLC’s Form 8-K, filed April 30, 2024: 14 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VERONA PHARMA PLC in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by VERONA PHARMA PLC

These tallies are VERONA PHARMA PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 30, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VERONA PHARMA PLC — official shareholder meeting results, meeting held April 26, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
1. To re-elect Lisa Deschamps as a Director of the Company 615,922,1532,039,440-- 780,158-- 99.7%Passed (calculated)—
2. To re-elect Martin Edwards as a Director of the Company 617,654,873309,040-- 777,838-- 99.9%Passed (calculated)—
3. To re-elect Sven Anders Ullman as a Director of the Company 590,081,65727,882,176-- 777,918-- 95%Passed (calculated)—
4. To re-elect Christina Ackerman as a Director of the Company 617,786,657169,976-- 785,118-- 99.9%Passed (calculated)—
5. To re-elect Michael Austwick as a Director of the Company 617,807,153170,296-- 764,302-- 99.9%Passed (calculated)—
6. To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2023 and the report of the auditors thereon (the "2023 U.K. Annual Report") 616,905,1431,179,344-- 657,264-- 99.8%Passed (calculated)—
7. To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended December 31, 2023, as set out on pages 36 to 57 of the 2023 U.K. Annual Report 593,000,12124,709,190-- 1,032,440-- 96%Passed (calculated)—
8. To receive and approve the U.K. Directors' Remuneration Policy, as set out on pages 47 to 57 of the 2023 U.K. Annual Report, which, if approved, will take effect upon conclusion of the AGM 592,664,31724,906,426-- 1,171,008-- 96%Passed (calculated)—
9. To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration (by way of fee) in accordance with Article 21.4 of the Company's Articles of Association to £750,000 per annum on an ongoing basis 589,238,58928,269,274-- 1,233,888-- 95%Passed (calculated)—
10. To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders 603,137,815195,320-- 15,408,616-- 99.9%Passed (calculated)—
11. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2024 618,024,71965,608-- 651,424-- 99.9%Passed (calculated)—
12. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers 594,069,52123,464,550-- 1,207,680-- 96%Passed (calculated)—
13. To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the "Companies Act") to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to co 588,880,42528,995,238-- 866,088-- 95%Passed (calculated)—
14. Subject to and conditional upon the passing of resolution 13 above, to authorize the Directors pursuant to Section 570 and 573 of the Companies Act to allot equity securities (as defined in Section 560 of the Companies Act) for cash pursuant to the authori 616,327,6271,576,996-- 837,128-- 99.7%Passed (calculated)—

Source: VERONA PHARMA PLC, Form 8-K, filed with the SEC on April 30, 2024 — read the filing on EDGAR.

How asset managers voted at the VERONA PHARMA PLC 2023-2024 meeting

126 asset managers disclosed a vote on at least one VERONA PHARMA PLC item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of VERONA PHARMA PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

To re-elect Christina Ackerman as a Director of the Company

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 617,786,657AGAINST: 169,976
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To re-elect Christina Ackermann as a director of the Company.

VERONA PHARMA PLC’s own tally for this item (“4. To re-elect Christina Ackerman as a Director of the Company”): 617,786,657 for, 169,976 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 9,297,330 for.

FOR
FOR: 9,297,330
Largest asset managers voting on “To re-elect Christina Ackermann as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,187,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To re-elect Lisa Deschamps as a Director of the Company

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 615,922,153AGAINST: 2,039,440
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To re-elect Lisa Deschamps as a director of the Company.

VERONA PHARMA PLC’s own tally for this item (“1. To re-elect Lisa Deschamps as a Director of the Company”): 615,922,153 for, 2,039,440 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 9,293,963 for, 3,367 against.

FOR
FOR: 9,293,963AGAINST: 3,367
Largest asset managers voting on “To re-elect Lisa Deschamps as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,187,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST21,2653,299 00Mixed
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To re-elect Martin Edwards as a Director of the Company

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 617,654,873AGAINST: 309,040
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To re-elect Martin Edwards as a director of the Company.

VERONA PHARMA PLC’s own tally for this item (“2. To re-elect Martin Edwards as a Director of the Company”): 617,654,873 for, 309,040 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 9,297,330 for.

FOR
FOR: 9,297,330
Largest asset managers voting on “To re-elect Martin Edwards as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,187,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To re-elect Michael Austwick as a Director of the Company

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 617,807,153AGAINST: 170,296
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To re-elect Michael Austwick as a director of the Company.

VERONA PHARMA PLC’s own tally for this item (“5. To re-elect Michael Austwick as a Director of the Company”): 617,807,153 for, 170,296 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 9,297,330 for.

FOR
FOR: 9,297,330
Largest asset managers voting on “To re-elect Michael Austwick as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,187,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To re-elect Sven Anders Ullman as a Director of the Company

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 590,081,657AGAINST: 27,882,176
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To re-elect Sven Anders Ullman as a director of the Company.

VERONA PHARMA PLC’s own tally for this item (“3. To re-elect Sven Anders Ullman as a Director of the Company”): 590,081,657 for, 27,882,176 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 9,297,330 for.

FOR
FOR: 9,297,330
Largest asset managers voting on “To re-elect Sven Anders Ullman as a director of the Company.” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,187,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration (by way of fee) in…

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 9 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 589,238,589AGAINST: 28,269,274
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To approve an increase in the maximum aggregate level of NonExecutive Director annual remuneration (by way of fee) in accordance with Article 21.4 of the Companys Articles of Association to 750,000 per annum on an ongoing basis.

VERONA PHARMA PLC’s own tally for this item (“9. To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration (by way of fee) in accordance with Article 21.4 of the Company's Articles of Association to £750,000 per annum on an ”): 589,238,589 for, 28,269,274 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 33 asset managers voting on “To approve an increase in the maximum aggregate level of NonExecutive Director annual remuneration (by way of ” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,243,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Fund voting reports, all 33 managers: 9,353,020 for. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To approve an increase in the maximum aggregate level of NonExecutive Director annual remuneration (by way of ” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ORBIMED ADVISORS LLC02,527,382 00Against
CIDEL ASSET MANAGEMENT INC5760 00For
Keel Point, LLC3100 00For

Institutional-manager reports, all 3 managers: 886 for, 2,527,382 against.

To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the…

No official matchCAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

99.3% of fund votes cast · no official result

FOR
Details: description as filed, votes by 34 asset managers

Description as filed by funds: To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if Section 561(1) of the Companies Act does not apply to any such allotment.

The 34 asset managers below reported 9,283,545 for, 69,785 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,283,545AGAINST: 69,785
Largest asset managers voting on “To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,243,5200 00For
Fidelity1,659,26365,320 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street04,458 00Against

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006…

Calculated outcomeCAPITAL STRUCTUREPassed (calculated)

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 588,880,425AGAINST: 28,995,238
Details: description as filed, official tally, votes by 20 asset managers

Description as filed by funds: To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of 8,345,745 (being up to a maximum of 166,914,908 shares representing 25% of the Companys existing ordinary share capital as at the close of business on March 13, 2024 (being the latest practicable date prior to publication of this document)).

VERONA PHARMA PLC’s own tally for this item (“13. To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the "Companies Act") to exercise all the powers of the Company to allot shares in the Company o”): 588,880,425 for, 28,995,238 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 6,130,936 for.

FOR
FOR: 6,130,936
Largest asset managers voting on “To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company o” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,243,5200 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
Hartford485,6790 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
Victory Capital1,9710 00For
Blackstone Alternative Investment Funds1,1000 00For
Principal1,0390 00For
MML SERIES INVESTMENT FUND6710 00For
Keel Point, LLC3100 00For
MassMutual1850 00For
Investment Managers Series Trust II1760 00For

To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006…

Calculated outcomeCAPITAL STRUCTUREPassed (calculated)

95% Majority: yes · of votes cast

FOR 95%
FOR: 588,880,425AGAINST: 28,995,238
Details: description as filed, official tally, votes by 14 asset managers

Description as filed by funds: To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds8,345,745 (being up to a maximum of 166,914,908 shares representing 25% of the Company's existing ordinary share capital as at the close of business on March 13, 2024 (being the latest practicable date prior to publication of this document)).

VERONA PHARMA PLC’s own tally for this item (“13. To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the "Companies Act") to exercise all the powers of the Company to allot shares in the Company o”): 588,880,425 for, 28,995,238 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 14 asset managers below reported 3,157,067 for, 65,327 against.

FOR
FOR: 3,157,067AGAINST: 65,327
Largest asset managers voting on “To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company o” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,659,26365,320 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
ALPS ETF Trust58,0060 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For
Invesco680 00For
Aberdeen07 00Against

To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2023 and…

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 616,905,143AGAINST: 1,179,344
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended 31 December 2023.

VERONA PHARMA PLC’s own tally for this item (“6. To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2023 and the report of the auditors thereon (the "2023 U.K. Annual Report")”): 616,905,143 for, 1,179,344 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 9,297,330 for.

FOR
FOR: 9,297,330
Largest asset managers voting on “To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended 31 December 2” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,187,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 594,069,521AGAINST: 23,464,550
Details: description as filed, official tally, votes by 126 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

VERONA PHARMA PLC’s own tally for this item (“12. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers”): 594,069,521 for, 23,464,550 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 33 asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,243,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM0541,647 00Against
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios0106,781 00Against
Neuberger Berman096,259 00Against
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST3,29921,265 00Mixed
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS8,0141,232 00Mixed
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Fund voting reports, all 33 managers: 8,585,836 for, 767,184 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 101 asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
RA CAPITAL MANAGEMENT, L.P.6,214,6700 00For
Vivo Capital, LLC3,610,1080 00For
ORBIMED ADVISORS LLC3,444,3630 00For
Wellington3,303,0900 00For
Deep Track Capital, LP3,187,4150 00For
PERCEPTIVE ADVISORS LLC2,936,9570 00For
Carlyle Group Inc.2,457,5000 00For
Fidelity2,255,2560 00For
MAVERICK CAPITAL LTD1,375,5570 00For
JENNISON ASSOCIATES LLC01,229,810 00Against
Janus Henderson1,139,5340 00For
Caligan Partners LP1,049,2160 00For
Federated Hermes1,043,8640 00For
Octagon Capital Advisors LP1,027,4680 00For
Ally Bridge Group (NY) LLC783,0830 00For
Woodline Partners LP752,9800 00For
Laurion Capital Management LP703,8850 00For
Hood River Capital Management LLC0506,798 00Against
American Century504,2580 00For
Affinity Asset Advisors, LLC412,9950 00For
Samsara BioCapital, LLC347,5000 00For
BOOTHBAY FUND MANAGEMENT, LLC326,6210 00For
RICE HALL JAMES & ASSOCIATES, LLC8,642266,798 00Against
Aisling Capital Management LP259,2600 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.254,9940 00For

Institutional-manager reports, all 101 managers: 39,050,422 for, 2,680,553 against, 177 withheld, 2,904 not voted. Showing the 25 largest; every one is in the interactive database (link above).

To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 593,000,121AGAINST: 24,709,190
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended 31 December 2023

VERONA PHARMA PLC’s own tally for this item (“7. To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended December 31, 2023, as set out on pages 36 to 57 of the 2023 U.K. Annual Report”): 593,000,121 for, 24,709,190 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 33 asset managers voting on “To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Repor” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,243,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM0541,647 00Against
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios0106,781 00Against
Neuberger Berman096,259 00Against
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST3,29921,265 00Mixed
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS8,0141,232 00Mixed
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Fund voting reports, all 33 managers: 8,585,836 for, 767,184 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 36 asset managers voting on “To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Repor” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP3,187,4150 00For
MAVERICK CAPITAL LTD1,375,5570 00For
ORBIMED ADVISORS LLC916,9810 00For
Hood River Capital Management LLC0506,798 00Against
Affinity Asset Advisors, LLC412,9950 00For
BOOTHBAY FUND MANAGEMENT, LLC326,6210 00For
Aisling Capital Management LP259,2600 00For
MOODY ALDRICH PARTNERS LLC234,4620 00For
PNC BANK, NATIONAL ASSOCIATION0212,000 00Against
Polar Asset Management Partners Inc.96,5000 00For
Treasurer of the State of North Carolina059,107 00Against
ENVESTNET ASSET MANAGEMENT INC024,007 00Against
US BANK NATIONAL ASSOCIATION23,1790 00For
Orion Porfolio Solutions, LLC18,5560 00For
Orion Portfolio Solutions, LLC18,5560 00For
S&CO INC12,0260 00For
BERKSHIRE ASSET MANAGEMENT LLC/PA08,000 00Against
D.A. DAVIDSON & CO.07,600 00Against
LPL Financial LLC06,967 00Against
TRUIST FINANCIAL CORP05,000 00Against
Matisse Capital4,4000 00For
Heck Capital Advisors, LLC4,1600 00For
JPMorgan2,9740 00For
Chicago Partners Investment Group LLC2,8090 00For
Centiva Capital, LP02,271 00Against

Institutional-manager reports, all 36 managers: 6,898,158 for, 833,616 against, 177 withheld. Showing the 25 largest; every one is in the interactive database (link above).

To receive and approve the U.K. Directors' Remuneration Policy, as set out on pages 47 to 57 of the 2023 U.K. Annual…

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 592,664,317AGAINST: 24,906,426
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To receive and approve the U.K. Directors' Remuneration Policy.

VERONA PHARMA PLC’s own tally for this item (“8. To receive and approve the U.K. Directors' Remuneration Policy, as set out on pages 47 to 57 of the 2023 U.K. Annual Report, which, if approved, will take effect upon conclusion of the AGM”): 592,664,317 for, 24,906,426 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 8,586,146 for, 767,184 against.

FOR
FOR: 8,586,146AGAINST: 767,184
Largest asset managers voting on “To receive and approve the U.K. Directors' Remuneration Policy.” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,243,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM0541,647 00Against
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios0106,781 00Against
Neuberger Berman096,259 00Against
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST3,29921,265 00Mixed
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS8,0141,232 00Mixed
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 603,137,815AGAINST: 195,320
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.

VERONA PHARMA PLC’s own tally for this item (“10. To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders”): 603,137,815 for, 195,320 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 9,353,330 for.

FOR
FOR: 9,353,330
Largest asset managers voting on “To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,243,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2024

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 618,024,719AGAINST: 65,608
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2024.

VERONA PHARMA PLC’s own tally for this item (“11. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2024”): 618,024,719 for, 65,608 against, per its Form 8-K filed April 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 9,353,330 for.

FOR
FOR: 9,353,330
Largest asset managers voting on “To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December” at VERONA PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,243,5200 00For
Fidelity1,724,5830 00For
Vanguard1,304,4060 00For
Federated Hermes1,043,8640 00For
Prudential/PGIM541,6470 00For
JANUS INVESTMENT FUND492,1270 00For
American Century487,4630 00For
Hartford485,6790 00For
BlackRock220,4360 00For
Legg Mason172,2000 00For
John Hancock113,0110 00For
Manager Directed Portfolios106,7810 00For
Neuberger Berman96,2590 00For
Nationwide76,5470 00For
ALPS ETF Trust58,0060 00For
Guardian Variable Products Trust45,7000 00For
New York Life34,2600 00For
CLEARWATER INVESTMENT TRUST24,5640 00For
AIG/SunAmerica18,7340 00For
Goldman Sachs17,4200 00For
PENN SERIES FUNDS INC16,7490 00For
TRUST FOR PROFESSIONAL MANAGERS9,2460 00For
BNY Mellon5,3000 00For
ProShares4,8430 00For
State Street4,4580 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Largest VERONA PHARMA PLC shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 647,372,062 shares outstanding at the time of that meeting.

Fund voting reports: top VERONA PHARMA PLC shareholders by shares voted on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED…”, 2023-2024
#Asset manager % of shares outstanding
1MUTUAL FUND SERIES TRUST 0.35%
2Fidelity 0.27%
3Vanguard 0.20%
4Federated Hermes 0.16%
5Prudential/PGIM 0.08%
6JANUS INVESTMENT FUND 0.08%
7American Century 0.08%
8Hartford 0.08%
9BlackRock 0.03%
10Legg Mason 0.03%
Institutional-manager reports: top VERONA PHARMA PLC shareholders by shares voted on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED…”, 2023-2024
#Asset manager % of shares outstanding
1RA CAPITAL MANAGEMENT, L.P. 0.96%
2Vivo Capital, LLC 0.56%
3ORBIMED ADVISORS LLC 0.53%
4Wellington 0.51%
5Deep Track Capital, LP 0.49%
6PERCEPTIVE ADVISORS LLC 0.45%
7Carlyle Group Inc. 0.38%
8Fidelity 0.35%
9MAVERICK CAPITAL LTD 0.21%
10JENNISON ASSOCIATES LLC 0.19%

Reported VERONA PHARMA PLC holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

VERONA PHARMA PLC holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
RA Capital Management affiliates60,031,808 9.27%Proxy statement (DEF 14A), proxy filed March 20, 2024
New Enterprise Associates affiliates46,447,651 7.17%Proxy statement (DEF 14A), proxy filed March 20, 2024
Growth Equity Opportunities Fund IV, LLC44,678,025 6.90%Schedule 13D, filed August 28, 2024
FMR LLC39,219,016 6.06%Proxy statement (DEF 14A), proxy filed March 20, 2024
David Zaccardelli, Pharm.D.12,667,592 1.96%Proxy statement (DEF 14A), proxy filed March 20, 2024
Mark W. Hahn11,756,576 1.82%Proxy statement (DEF 14A), proxy filed March 20, 2024
BlackRock3,826,710 0.59%Form 13F, quarter ended March 31, 2024
Kathleen Rickard, M.D.2,273,224 0.35%Proxy statement (DEF 14A), proxy filed March 20, 2024
Goldman Sachs1,935,278 0.30%Form 13F, quarter ended March 31, 2024
Morgan Stanley1,575,904 0.24%Form 13F, quarter ended March 31, 2024

Percentages above are of 647,372,062 shares outstanding, as reported by VERONA PHARMA PLC on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At VERONA PHARMA PLC's shareholder meeting held April 26, 2024, in the 2023-2024 proxy season, 126 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 974 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VERONA PHARMA PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 30, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VERONA PHARMA PLC’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

VERONA PHARMA PLC proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “VERONA PHARMA PLC 2024 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/verona-pharma-plc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.